Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 4Recurrence 3Solid Tumor Malignancy 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdoid Tumor 1Recurrent Squamous Cell Lung Carcinoma 1Neurofibrosarcoma 1Neoplasm, Residual 1Lymphoma, Large B-Cell, Diffuse 1Liposarcoma 1Immunoglobulin Light-chain Amyloidosis 1Central Nervous System Neoplasms 1Amyloidosis 1Alzheimer Disease 1

Interventions

selinexor 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Recurrent Squamous Cell Lung Carcinoma × selinexor × Clear all
NCT02536495 2015-10-30

Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 1/2 Withdrawn

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡